FuzeBio Journal
Clinical catalysts, valuation deep-dives, and a clear-eyed look at where biotech is heading — written for investors who want the signal, not the noise.
Definium's Panorama trial cut anxiety scores 5.1 points more than placebo, and the stock gave back most of a 12% opening gain by the close. The result is real. The question the FDA will ask is whether two-thirds of the treated patients knew they were treated, and the release already tells you the answer.
Loss of exclusivity is the date a drug stops being the only version of itself for sale, and it is usually not the patent expiry date. Merck's own filing says Keytruda, which is 49% of its sales, meets that date between 2028 and 2029. AbbVie's numbers show what the three years after one actually look like.
The maximum fair price is the price Medicare sets for a drug it picked for negotiation, and 'fair' is a label in a statute rather than a market judgment. The ceiling runs from 75 percent down to 40 percent of a benchmark depending on how old the drug is, and Bristol Myers Squibb's own annual report puts the words in quotation marks.
A priority review voucher is a coupon the FDA gives a company for approving a rare pediatric drug, and the company can sell it to a stranger. Four recent sales ran from $150 million to $205 million. What the buyer pays the FDA on top, who actually receives the money, and the expiry date written into the statute.
A pre-funded warrant is a share the buyer has already paid for and has not collected. It is usually the least alarming thing in the offering it arrives in — and the same press release often contains a second warrant that is not. Here is how to tell them apart.
Cash runway is how long a company's money lasts at its current rate of spending. In a biotech press release it is not the balance divided by the burn — it is the company's own estimate under a plan it has not shown you, and the two numbers routinely disagree. Here is what the sentence is legally, what it leaves out, and the one version of it worth reading.
A complete response letter is the FDA telling a company it will not approve an application in its present form. It is not a rejection, it is not final, and two letters carrying the same name can mean a facility inspection or a whole new phase 3 trial. Here is what the letter contains, what the company has to do next, and how long the clock runs.
An adcom is an FDA advisory committee meeting: outside experts discuss a pending application and usually vote on it. The vote binds nobody. Two panels met on consecutive days in July and voted opposite ways — what the vote actually is, where to read the documents yourself, and how often the agency follows the advice.
A shelf registration is a standing SEC permission — usually a Form S-3 — that lets a company sell new shares with no notice. It is the paperwork behind every biotech raise that lands the morning after good data. Three worked examples and where each of them appears on EDGAR.
The phrase describes a price that rises on anticipation and falls when the event finally arrives. In biotech it gets applied to five different things that look identical from the outside — and four of the five leave evidence in documents you can read.
Topline data is the company's own first summary of a trial result — the primary endpoint, one statistic, a sentence about safety — released weeks or months before anyone outside the company sees the full dataset. Here is what those releases contain, what they leave out, and when the rest arrives.
Reports that AstraZeneca and Bristol Myers Squibb discussed a roughly $400 billion combination sent their stocks in opposite directions the same week — before either company confirmed a thing. What a divided market reaction to an unconfirmed deal actually tells you, and what each company needed this to be about.
The FDA cleared Bristol Myers Squibb's first CELMoD therapy for multiple myeloma on 13 August, based on how many patients had no detectable cancer left — not on how long they lived. Here's what accelerated approval on that marker actually commits BMS to, and why the company needs this drug to work.
The radiopharma deal announced on 3 August puts a third of its headline premium into contingent value rights. Here is how to read a CVR, and what Lantheus's own second-quarter numbers say about whether the milestones are reachable.
The FDA's goal date for Replimune's melanoma therapy was 2 August. It came and went. What a missed decision date actually means, why the 10-3 panel vote was narrower than it sounds, and the cash question sitting underneath both outcomes.
Selinexor's phase 3 endometrial cancer trial showed a five-month gap in median progression-free survival and missed anyway. The distance between what the medians look like and what the statistics allow is the lesson — and the balance sheet explains the size of the move.
A topline press release is not the trial. A practical framework for reading a trial result — the question it was designed to answer, effect size, statistics, safety, and commercial context — before the headline moves the stock.